Skip to main content

Together we are beating cancer

Donate now

Targeted therapies

Showing 12 out of 73 results
3D visualisation of thyroid cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

by Harry Jenkins | News | 1 October 2021

1 October 2021

  • Science & Technology
  • Health & Medicine

Innovative cancer spinouts: 3 new projects get green light

The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours. The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.

by Cancer Research UK | News | 13 August 2021

13 August 2021

The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy. The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy.

by Harry Jenkins | News | 22 July 2021

22 July 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021

Lung cancer cell

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma. The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

by Cancer Research UK | News | 21 January 2021

21 January 2021